KIT and cancer: It is now possible to attack specific molecular targets in selected cancers, such as gastrointestinal stromal tumours (GISTs) using imatinib [12], a molecule that specifically targets the surface tyrosine kinase receptor c-Kit (CD117), now recognised as the hallmark immunohistochemical cell marker of GIST.